Wealth Architects LLC grew its stake in Cencora, Inc. (NYSE:COR – Free Report) by 14.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,573 shares of the company’s stock after buying an additional 195 shares during the quarter. Wealth Architects LLC’s holdings in Cencora were worth $472,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after buying an additional 787,858 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Cencora by 7.2% in the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock valued at $1,507,599,000 after buying an additional 363,402 shares during the period. Boston Partners lifted its position in shares of Cencora by 8.1% in the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after purchasing an additional 404,093 shares in the last quarter. Invesco Ltd. lifted its position in shares of Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Cencora by 9.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after purchasing an additional 154,311 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Insider Buying and Selling at Cencora
In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares in the company, valued at $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,993 shares of company stock worth $16,292,923. Corporate insiders own 10.80% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Report on Cencora
Cencora Stock Performance
NYSE COR opened at $318.01 on Monday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm’s fifty day moving average price is $296.99 and its two-hundred day moving average price is $291.87. Cencora, Inc. has a 1 year low of $221.95 and a 1 year high of $319.68. The firm has a market capitalization of $61.66 billion, a P/E ratio of 32.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63.
Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s payout ratio is currently 22.63%.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
- Five stocks we like better than Cencora
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Microsoft 365 Premium Marks the Next Phase of AI Monetization
- Following Congress Stock Trades
- Could Target’s Week of Discounts Come Full Circle for Investors?
- Energy and Oil Stocks Explained
- 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.